Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

ANALYST COVERAGE

bofa-securities-maintains-buy-on-slm-corporation-(slmbp)-march-9-2026

BofA Securities Maintains Buy on SLM Corporation (SLMBP) March 9 2026

Mar 10, 2026

BofA Securities maintained a Buy on SLM Corporation (SLMBP) on March 09, 2026. The SLMBP analyst rating note…

Read more
assessing-itron-(itri)-valuation-after-new-analyst-coverage-and-utilityiq-module-expansion

Assessing Itron (ITRI) Valuation After New Analyst Coverage And UtilityIQ Module Expansion

Mar 10, 2026

Itron (ITRI) has drawn fresh attention after expanding its UtilityIQ Application Suite to support new Cellular 500G and…

Read more
oppenheimer,-cowen,-hc.-wainwright-maintain-buy/outperform-on-olma-march-2026

Oppenheimer, Cowen, H.C. Wainwright Maintain Buy/Outperform on OLMA March 2026

Mar 10, 2026

OLMA analyst rating updates on March 9, 2026 show three firms kept positive calls on Olema Pharmaceuticals, Inc.…

Read more
william-blair-maintains-outperform-for-caterpillar-inc.-(cat)-march-9,-2026

William Blair Maintains Outperform for Caterpillar Inc. (CAT) March 9, 2026

Mar 10, 2026

The latest CAT analyst rating shows William Blair maintained an Outperform on Caterpillar Inc. (CAT) on March 9,…

Read more
oppenheimer-maintains-outperform-on-abeona-therapeutics-(abeo)-pt-$22-march-2026

Oppenheimer Maintains Outperform on Abeona Therapeutics (ABEO) PT $22 March 2026

Mar 10, 2026

Oppenheimer maintained an Outperform rating on Abeona Therapeutics Inc. (ABEO) and raised its price target to $22 on…

Read more
oppenheimer-maintains-outperform-on-trvi-(march-09,-2026)

Oppenheimer Maintains Outperform on TRVI (March 09, 2026)

Mar 10, 2026

Oppenheimer maintained an Outperform on Trevi Therapeutics, Inc. (TRVI) on March 09, 2026 after a 10% near-term share…

Read more
william-blair,-barclays-keep-outperform/overweight-on-microsoft-(msft)-mar-2026

William Blair, Barclays Keep Outperform/Overweight on Microsoft (MSFT) Mar 2026

Mar 9, 2026

MSFT analyst rating update: William Blair reiterated Outperform and Barclays kept Overweight on Microsoft Corporation on March 09,…

Read more
leerink-maintains-market-perform-on-biomarin-(bmrn)-march-09,-2026

Leerink Maintains Market Perform on BioMarin (BMRN) March 09, 2026

Mar 9, 2026

Leerink Partners on March 09, 2026 maintained its Market Perform rating on BioMarin Pharmaceutical Inc. (BMRN). The BMRN…

Read more
h-world,-netflix-and-jd.com-are-getting-fresh-analyst-coverage-across-global-consumer-markets

H World, Netflix and JD.com Are Getting Fresh Analyst Coverage Across Global Consumer Markets

Mar 9, 2026

Joel South Mon, March 9, 2026 at 11:28 AM EDT 4 min read H World (HTHT) upgraded to…

Read more
h-world,-netflix-and-jd.com-are-getting-fresh-analyst-coverage-across-global-consumer-markets

H World, Netflix and JD.com Are Getting Fresh Analyst Coverage Across Global Consumer Markets

Mar 9, 2026

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions…

Read more
h-world,-netflix-and-jd.com-are-getting-fresh-analyst-coverage-across-global-consumer-markets

H World, Netflix and JD.com Are Getting Fresh Analyst Coverage Across Global Consumer Markets

Mar 9, 2026

24/7 Wall St. (24/7 Wall St.) Quick Read H World (HTHT) upgraded to Buy by UBS, $62.40 target,…

Read more
wolfe-research-initiates-cava-stock-coverage-with-outperform-rating

Wolfe Research initiates Cava stock coverage with outperform rating

Mar 9, 2026

Wolfe Research initiates Cava stock coverage with outperform rating

Read more
  1. Pages:
  2. «
  3. 1
  4. ...
  5. 12
  6. 13
  7. 14
  8. 15
  9. 16
  10. 17
  11. 18
  12. ...
  13. 377
  14. »

Posts pagination

Newer posts Page 1 … Page 15 … Page 377 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.